乳腺癌新辅助化疗：终极“间谍”。 - Suppr

Suppr

超能文献

Neoadjuvant Chemotherapy for Breast Cancer: The Ultimate "Spy".

作者信息

Fisher Carla Suzanne

机构信息

Indiana University School of Medicine, 1030 W. Michigan St., Suite 4400, Indianapolis, IN, 46202, USA.

出版信息

Ann Surg Oncol. 2022 Oct;29(11):6508-6510. doi: 10.1245/s10434-022-12153-4. Epub 2022 Aug 4.

DOI:10.1245/s10434-022-12153-4

PMID:35925535

Abstract

摘要

相似文献

Neoadjuvant Chemotherapy for Breast Cancer: The Ultimate "Spy".乳腺癌新辅助化疗：终极“间谍”。

Ann Surg Oncol. 2022 Oct;29(11):6508-6510. doi: 10.1245/s10434-022-12153-4. Epub 2022 Aug 4.

The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.发展中国家乳腺癌新辅助化疗的实际情况：来自印度一家三级癌症中心的 80 例乳腺癌报告。

J Cancer Res Clin Oncol. 2014 Oct;140(10):1777-82. doi: 10.1007/s00432-014-1724-1. Epub 2014 Jun 4.

Significance of iodine symporter for prognosis of the disease course and efficacy of neoadjuvant chemotherapy in patients with breast cancer of luminal and basal subtypes.碘转运体对管腔型和基底型乳腺癌患者疾病进程预后及新辅助化疗疗效的意义。

Exp Oncol. 2017 Mar;39(1):65-68.

On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer.治疗中的生物标志物可改善乳腺癌新辅助化疗反应的预测。

Breast Cancer Res. 2019 Jun 14;21(1):73. doi: 10.1186/s13058-019-1159-3.

Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?早期反应评估能否指导早期乳腺癌的新辅助化疗？

J Natl Cancer Inst. 2008 Apr 16;100(8):521-3. doi: 10.1093/jnci/djn098. Epub 2008 Apr 8.

[HER2-positive breast cancer: standard and double targeted therapy].[人表皮生长因子受体2阳性乳腺癌：标准治疗与双重靶向治疗]

Vopr Onkol. 2013;59(3):341-6.

[San Antonio Breast Cancer Symposium 2003. New therapeutic prospects in the treatment of early-stage breast cancer].[2003年圣安东尼奥乳腺癌研讨会。早期乳腺癌治疗的新治疗前景]

Tumori. 2004 Jan-Feb;90(1):suppl 1-16.

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.曲妥珠单抗、帕妥珠单抗和化疗新辅助治疗与曲妥珠单抗恩美曲妥珠单抗和帕妥珠单抗联合用于 HER2 阳性乳腺癌患者（KRISTINE）：一项随机、开放标签、多中心、III 期临床试验。

Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23.

Medical treatment of early breast cancer. IV: neoadjuvant treatment.早期乳腺癌的医学治疗。IV：新辅助治疗。

BMJ. 2006 Jan 28;332(7535):223-4. doi: 10.1136/bmj.332.7535.223.

[Adjuvant chemotherapy in breast cancer. International perspective].[乳腺癌的辅助化疗。国际视角]

Tumori. 2000 Nov-Dec;86(6 Suppl 1):S7-8. doi: 10.1177/03008916000866S102.

引用本文的文献

The Current Role of Neoadjuvant Chemotherapy in the Management of HER2-Positive, Triple-Negative, and Micropapillary Breast Cancer: A Narrative Review.新辅助化疗在HER2阳性、三阴性及微乳头型乳腺癌治疗中的当前作用：一项叙述性综述

Cureus. 2023 Nov 30;15(11):e49742. doi: 10.7759/cureus.49742. eCollection 2023 Nov.

本文引用的文献

Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer.新辅助化疗后影像引导下乳腺活检预测残余癌的准确性。

JAMA Surg. 2020 Dec 1;155(12):e204103. doi: 10.1001/jamasurg.2020.4103. Epub 2020 Dec 16.

What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials?什么构成癌症临床试验中有效的替代终点？

JAMA Oncol. 2020 Sep 1;6(9):1334-1335. doi: 10.1001/jamaoncol.2020.1847.

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.卡培他滨辅助治疗新辅助化疗后的乳腺癌。

N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645.

A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.新辅助全身治疗后可消除乳腺癌手术的例外响应者的临床可行性试验。

Ann Surg. 2018 May;267(5):946-951. doi: 10.1097/SLA.0000000000002313.

Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.使用夹闭淋巴结的选择性评估对淋巴结阳性乳腺癌患者新辅助治疗后腋窝评估进行改进：靶向腋窝清扫的实施

J Clin Oncol. 2016 Apr 1;34(10):1072-8. doi: 10.1200/JCO.2015.64.0094. Epub 2016 Jan 25.

Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).识别并切除夹闭淋巴结可降低接受新辅助化疗的淋巴结阳性乳腺癌（T0-T4，N1-N2）患者前哨淋巴结手术的假阴性率：美国外科医师学会肿瘤学组Z1071（联盟）研究结果

Ann Surg. 2016 Apr;263(4):802-7. doi: 10.1097/SLA.0000000000001375.

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.肿瘤完全缓解通过亚组更有效地预测无复发生存：来自 I-SPY 1 试验——CALGB 150007/150012、ACRIN 6657 的结果。

J Clin Oncol. 2012 Sep 10;30(26):3242-9. doi: 10.1200/JCO.2011.39.2779. Epub 2012 May 29.

Breast cancer molecular subtypes respond differently to preoperative chemotherapy.乳腺癌分子亚型对术前化疗的反应不同。

Clin Cancer Res. 2005 Aug 15;11(16):5678-85. doi: 10.1158/1078-0432.CCR-04-2421.

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.在术前多柔比星和环磷酰胺基础上序贯添加术前多西他赛对肿瘤反应的影响：国家外科辅助乳腺和肠道项目协议B-27的初步结果

J Clin Oncol. 2003 Nov 15;21(22):4165-74. doi: 10.1200/JCO.2003.12.005. Epub 2003 Oct 14.

Combination chemotherapy as an adjuvant treatment in operable breast cancer.联合化疗作为可手术乳腺癌的辅助治疗方法。

N Engl J Med. 1976 Feb 19;294(8):405-10. doi: 10.1056/NEJM197602192940801.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验